ALEC (Alector) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALEC Alector Inc ALEC
28 GF Score
Price $1.50
GF Value $0.72
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alector Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ALEC
28GF Score
Alector Inc ALEC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alector (ALEC) Overvalued in 2026?

Based on GuruFocus' analysis, Alector stock appears to be overvalued. The current stock price of $1.50 is trading 108.3% above its estimated GF Value™ of $0.72. GuruFocus considers Alector to be Significantly Overvalued.

Key valuation signals for ALEC:

  • Short Ratio:
  • GF Value™: $0.72 vs. price of $1.50 (108.3% above fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the ALEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alector Business Description

Other Exchanges 0Z2:Germany
Address 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
28GF Score

Get the complete analysis for ALEC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price
$0.72
GF Value